“If I were in your shoes or in Commissioner Gottlieb’s shoes I wouldn’t wait another day to require a warning on all [talc-containing cosmetic] products,” EWG’s Scott Faber told a House Oversight and Reform subcommittee March 12, while maintaining that large-scale regulatory changes are what's truly needed to protect users of talcum powders and other personal-care items.
Concerns about talc-containing products were the basis for a March 12 hearing convened by a House Oversight and Reform subcommittee, but the larger discussion pertained to the regulatory framework for cosmetics and FDA’s authorities – or lack thereof – under current law.
In its inaugural hearing, the Subcommittee on Economic and Consumer Policy – “created to focus attention on pocketbook issues that...
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
Legislator education is key to checking state bills that overreach, says Ross, executive VP of government affairs at the Personal Care Products Council, discussing the rising tide of US state bills aimed at restricting ingredient use.
FDA reminds companies which registered with agency solely to manufacture OTC sanitizers during COVID-19 public health emergency they will be subject to FY2025 OTC monograph user fees if they don’t delist and deregister as monograph drug manufacturers by 12 a.m. on 31 December.
With monographs@FDA portal down, agency moves to NextGen and extends comment period through 27 September for first OTC monograph change it proposed using its overhauled program other than 32 monographs finalizations required in 2020 legislation authorizing overhaul.
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.
